Skip to main content

Advertisement

SpringerLink
Log in

Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting

  • Laboratory Investigation - Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Human melanoma proteoglycan (HMP), a melanoma-associated antigen, is expressed in both human melanomas and gliomas. We used HMP-specific monoclonal antibody (mAb) VT68.2 to investigate whether murine GL261 cerebral gliomas express the HMP homologue AN2 and to determine whether AN2 could be targeted for selective delivery of radiation in vivo. HMP-specific mAb VT68.2 stained murine GL261 glioma cells grown in culture and intracerebrally in syngeneic C57BL/6 mice. Positron emission tomography with radiolabeled mAb VT68.2 showed high-contrast, positive images of gliomas against a negative background. At 96 h after injection, glioma uptake of radiolabeled mAb VT68.2 was 10× greater than that of the isotype control mAb and 20× greater than that detected in normal cerebral tissue. Our results show murine GL261 cerebral gliomas express AN2 and HMP-specific mAb VT68.2 accumulates selectively and specifically at high concentration and is retained within murine cerebral gliomas. Thus, HMP is a potential target for antibody-mediated selective delivery of radiation to cerebral gliomas in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136. doi:10.1200/JCO.2007.11.8554

    Article  PubMed  CAS  Google Scholar 

  2. Fenstermaker RA, Ciesielski MJ (2004) Immunotherapeutic strategies for malignant glioma. Cancer Control 11:181–191

    PubMed  Google Scholar 

  3. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD (1995) Tumor antigens in astrocytic gliomas. Glia 15:244–256. doi:10.1002/glia.440150306

    Article  PubMed  CAS  Google Scholar 

  4. Chai DD, Merchant RE, Rand R et al (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143–2152

    Google Scholar 

  5. Sasaki M, Nakahira K, Kawano Y et al (2001) MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res 61:4809–4814

    PubMed  CAS  Google Scholar 

  6. Prins RM, Odesa SK, Liau LM (2003) Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63:8487–8491

    PubMed  CAS  Google Scholar 

  7. Colapinto EV, Zalutsky MR, Archer GE et al (1990) Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab′)2 fragments of monoclonal antibody Mel-14. Cancer Res 50:1822–1827

    PubMed  CAS  Google Scholar 

  8. Schrappe M, Bumol TF, Apelgren LD et al (1992) Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 52:3838–3844

    PubMed  CAS  Google Scholar 

  9. Hjortland GO, Garman-Vik SS, Juell S et al (2004) Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg 100:320–327

    Article  PubMed  CAS  Google Scholar 

  10. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S (2004) Human high molecular weight-melanoma-associated antigen (HMP): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24:267–296. doi:10.1615/CritRevImmunol.v24.i4.40

    Article  PubMed  CAS  Google Scholar 

  11. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA, Gladson CL (1991) Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51:4986–4993

    PubMed  CAS  Google Scholar 

  12. Shoshan Y, Nishiyama A, Chang A et al (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 96:10361–10366. doi:10.1073/pnas.96.18.10361

    Article  PubMed  CAS  Google Scholar 

  13. Chekenya M, Rooprai HK, Davies D, Levine JM, Butt AM, Pilkington GJ (1999) The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. Int J Dev Neurosci 17:421–435. doi:10.1016/S0736-5748(99)00019-2

    Article  PubMed  CAS  Google Scholar 

  14. Chekenya M, Enger PO, Thorsen F et al (2002) The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol 28:367–380. doi:10.1046/j.1365-2990.2002.00412.x

    Article  PubMed  CAS  Google Scholar 

  15. Pluschke G, Vanek M, Evans A et al (1996) Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93:9710–9715. doi:10.1073/pnas.93.18.9710

    Article  PubMed  CAS  Google Scholar 

  16. Nishiyama A, Dahlin KJ, Prince JT, Johnstone SR, Stallcup WB (1991) The primary structure of NG2, a novel membrane-spanning proteoglycan. J Cell Biol 114:359–371. doi:10.1083/jcb.114.2.359

    Article  PubMed  CAS  Google Scholar 

  17. Stegmuller J, Schneider S, Hellwig A, Garwood J, Trotter J (2002) AN2, the murine homologue of NG2, is a surface antigen on glial precursor cells implicated in control of cell migration. J Neurocytol 31:497–505. doi:10.1023/A:1025743731306

    Article  PubMed  Google Scholar 

  18. Chekenya M, Hjelstuen M, Enger PO et al (2002) NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J 16:586–588

    PubMed  CAS  Google Scholar 

  19. Chekenya M, Immervoll H (2007) NG2/HMP proteoglycan as a cancer therapeutic target. Methods Mol Biol 361:93–117

    PubMed  CAS  Google Scholar 

  20. Temponi M, Gold AM, Ferrone S (1992) Binding parameters and idiotypic profile of the whole immunoglobulin and Fab′ fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. Cancer Res 52:2497–2503

    PubMed  CAS  Google Scholar 

  21. Kusama M, Kageshita T, Chen ZJ, Ferrone S (1989) Characterization of syngeneic antiidiotypic monoclonal antibodies to murine antihuman high molecular weight-melanoma associated antigen monoclonal antibodies. J Immunol 143:3844–3852

    PubMed  CAS  Google Scholar 

  22. Ghose T, Ferrone S, Blair AH et al (1991) Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen. Cancer Immunol Immunother 34:90–96. doi:10.1007/BF01741341

    Article  PubMed  CAS  Google Scholar 

  23. Siccardi AG, Buraggi GL, Callegaro L et al (1986) Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res 46:4817–4822

    PubMed  CAS  Google Scholar 

  24. Szatmari T, Lumniczky K, Desaknai S et al (2006) Detailed characterization of the murine glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 97:546–553. doi:10.1111/j.1349-7006.2006.00208.x

    Article  PubMed  CAS  Google Scholar 

  25. Candolfi M, Curtin JF, Nichols WS et al (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85:133–148. doi:10.1007/s11060-007-9400-9

    Article  PubMed  Google Scholar 

  26. Cha S, Johnson G, Wadghiri YZ et al (2003) Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 49:848–855. doi:10.1002/mrm.10446

    Article  PubMed  Google Scholar 

  27. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 8:85–95

    Article  PubMed  CAS  Google Scholar 

  28. Sajjad M, Bars E, Nabi HA (2006) Optimization of 124I production via 124Te(p, n)124I reaction. Appl Radiat Isot 64:965–970. doi:10.1016/j.apradiso.2006.04.004

    Article  PubMed  CAS  Google Scholar 

  29. Vaidyanathan G, Zalutsky MR (1990) Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. Bioconjug Chem 1:387–393. doi:10.1021/bc00006a004

    Article  PubMed  CAS  Google Scholar 

  30. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77–89. doi:10.1016/0022-1759(84)90435-6

    Article  PubMed  CAS  Google Scholar 

  31. Kim JS, Lee JS, Im KC et al (2007) Performance measurement of the microPET focus 120 scanner. J Nucl Med 48:1527–1535. doi:10.2967/jnumed.107.040550

    Article  PubMed  Google Scholar 

  32. Moshakis V, McIlhinney R, Raghavan D, Neville AM (1981) Monoclonal antibodies to detect human tumours: an experimental approach. J Clin Pathol 34:314–319. doi:10.1136/jcp.34.3.314

    Article  PubMed  CAS  Google Scholar 

  33. Jones TR, Ruoslahti E, Schold SC, Bigner DD (1982) Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res 42:168–177

    PubMed  CAS  Google Scholar 

  34. Dawson MR, Polito A, Levine JM, Reynolds R (2003) NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci 24:476–488. doi:10.1016/S1044-7431(03)00210-0

    Article  PubMed  CAS  Google Scholar 

  35. Stallcup WB, Beasley L (1987) Bipotential glial precursor cells of the optic nerve express the NG2 proteoglycan. J Neurosci 7:2737–2744

    PubMed  CAS  Google Scholar 

  36. Reardon DA, Akabani G, Coleman RE et al (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24:115–122. doi:10.1200/JCO.2005.03.4082

    Article  PubMed  CAS  Google Scholar 

  37. Quang TS, Brady LW (2004) Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58:972–975. doi:10.1016/j.ijrobp.2003.09.096

    PubMed  CAS  Google Scholar 

  38. Riva P, Arista A, Sturiale C et al (1992) Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer 51:7–13. doi:10.1002/ijc.2910510103

    Article  PubMed  CAS  Google Scholar 

  39. Yuan H, Gaber MW, Boyd K, Wilson CM, Kiani MF, Merchant TE (2006) Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys 66:860–866. doi:10.1016/j.ijrobp.2006.06.043

    PubMed  Google Scholar 

  40. Petronzelli F, Pelliccia A, Anastasi AM et al (2005) Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res 11:7137s–7145s. doi:10.1158/1078-0432.CCR-1004-0007

    Article  PubMed  CAS  Google Scholar 

  41. Grana C, Chinol M, Robertson C et al (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–212. doi:10.1038/sj.bjc.6600047

    Article  PubMed  CAS  Google Scholar 

  42. Sundaresan G, Yazaki PJ, Shively JE et al (2003) 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44:1962–1969

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by research grants NS049309 awarded to RAF by the National Institute of Neurological Disorders and Stroke (NIH/NINDS) and CA105500 awarded to SF by the National Cancer Institute. Additional support provided by the Roswell Park Cancer Institute Cancer Center Support Grant CA16056-29 (NIH-NCI), the Roswell Park Alliance Foundation and the Linda Scime Neurosurgery Endowment Fund. The authors would like to thank Rolf F. Barth, MD for his generous gift of GL261 glioma cells and John Luisi, CNMT for the assistance with microPET data acquisition.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, School of Medicine and Biomedical Sciences, State University of New York, University at Buffalo, Buffalo, NY, USA

    Asit K. Paul, Munawwar Sajjad & Hani Abdel-Nabi

  2. Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA

    Asit K. Paul

  3. Department of Neurosurgery, School of Medicine and Biomedical Sciences, State University of New York, University at Buffalo, Buffalo, NY, USA

    Michael J. Ciesielski & Robert A. Fenstermaker

  4. Department of Neurosurgery, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA

    Michael J. Ciesielski & Robert A. Fenstermaker

  5. Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA

    Michael J. Ciesielski, Xinhui Wang & Soldano Ferrone

Authors
  1. Asit K. Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Ciesielski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Munawwar Sajjad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinhui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soldano Ferrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hani Abdel-Nabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert A. Fenstermaker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Ciesielski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paul, A.K., Ciesielski, M.J., Sajjad, M. et al. Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J Neurooncol 94, 21–30 (2009). https://doi.org/10.1007/s11060-009-9798-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-9798-3

Keywords

Search

Navigation